Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Update

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 62,681 shares, a decrease of 64.2% from the January 15th total of 175,260 shares. Based on an average trading volume of 80,567 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.3% of the shares of the stock are short sold. Currently, 1.3% of the shares of the stock are short sold. Based on an average trading volume of 80,567 shares, the days-to-cover ratio is currently 0.8 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Redhill Biopharma in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of Redhill Biopharma

An institutional investor recently bought a new position in Redhill Biopharma stock. Gagnon Securities LLC purchased a new position in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 17,822 shares of the biotechnology company’s stock, valued at approximately $39,000. Gagnon Securities LLC owned approximately 0.54% of Redhill Biopharma as of its most recent SEC filing. Institutional investors own 7.20% of the company’s stock.

Redhill Biopharma Stock Up 6.3%

Shares of RDHL stock opened at $1.02 on Friday. The stock has a 50 day moving average of $1.19 and a 200-day moving average of $1.35. The firm has a market cap of $5.21 million, a PE ratio of 0.00 and a beta of 4.91. Redhill Biopharma has a 12 month low of $0.91 and a 12 month high of $5.75.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.